Citations

Clear

45 citation(s) found for "Sarosiek, I".

Predominant Symptom in Gastroparesis: Relationships to Quality of Life, Treatments, and Outcome
Parkman, Henry P., Wilson, L., Grover, Madhusudan, Chumpitazi, Bruno P. , Burton‐Murray, Helen, Sarosiek, I, Moshiree, Baha, Preidis, Geoffrey A. , Shulman, R. J., Miriel, Laura , Shade, Dave, Kuo, Braden, McCallum, Richard W., Pasricha, Pankaj J. , Parkman, Henry P. , Parkman, H P , Hasler, William L. , Chumpitazi, Bruno P , Burton-Murray, Helen , Preidis, Geoffrey A , Wilson, Laura A., Grover, Madhusudan , Moshiree, Baha , Kuo, Braden , McCallum, Richard W. , Abell, Thomas L.

Mayo Clinic

Neurogastroenterology & Motility | March 16, 2026 | Volume: 38 | Issue: 3 | Pages: No page available

10.1111/nmo.70287 | PMID 41833524 Get It

ABSTRACT Background Patients with gastroparesis (Gp) can have a variety of symptoms. Apart from use of prokinetics, symptomatic therapies for the predominant symptom (PrS) are used. Aims (1) To classify Gp patients based on their PrS; (2) To determine differences in Gp symptoms, gastric emptying (GE), quality of life (QOL), treatments, and symptom improvement among Gp patients with different PrS. Methods Gp patients were enrolled in a multicenter registry and followed for 96‐weeks. Patients recorded their PrS and completed questionnaires assessing symptoms and QOL at enrollment and at follow up visits. Results Of 1013 Gp patients (361 diabetic, 607 idiopathic, 45 post‐fundoplication), the PrS were nausea (31%), vomiting (20%), abdominal pain (20%), bloating (9%), fullness (4%), GERD (4%), constipation (3%). Abdominal pain was more often a PrS in idiopathics, whereas vomiting was more often a PrS in diabetics. QOL scores were lower in the abdominal pain PrS group. PrS was associated with greater use of directed symptomatic treatment (antiemetic agents and gastric electrical stimulation for nausea and vomiting, prokinetic agents for vomiting and fullness, and constipation medications for constipation). Of 555 patients followed over 48 weeks, GCSI improved by ≥ 1 in 26% overall, more often in patients with initial PrS of nausea (32%) and bloating (35%) and less often for initial PrS of fullness (13%) or abdominal pain (15%). Conclusions In Gp patients, the most common PrS were nausea, vomiting, and abdominal pain. PrS is associated with QOL, treatments utilized, and patient outcomes. Thus, the PrS of a patient with Gp provides useful information about their present condition and future outcome.
Accelerometric Assessment of Gastric Contractility Using the Atmo Wireless Motility Capsule
Abell, Thomas, Attaluri, Ashok, Chey, William D., Cline, Michael, Gearry, Richard B., Gibson, Peter R., Ho, Vincent, Lee, Allen A., Lembo, Anthony J, Masoud, Amir , McCallum, R, Moshiree, Baharak, Quigley, Eamonn M. M., Sanchez, Mayra, SAROSIEK, IRENE, Stocker, Abigail, Surjanhata, Brian , Kuo, Braden, Lembo, Anthony , Lee, Allen , Ho, Vincent , Hasler, William L. , Gibson, Peter R , Ho, Vincent , Lembo, Anthony , Surjanhata, Brian C , Lee, Allen A , Chey, William D. , Cline, Michael, Gearry, Richard B. , Moshiree, Baharak , Quigley, Eamonn M.M. , Rao, Satish R. , Thwaites, Phoebe A. , Zhou, Jerry , Kuo, Braden

Mayo Clinic

Neurogastroenterology & Motility | February 12, 2026 | Volume: 38 | Issue: 2 | Pages: No page available

10.1111/nmo.70255 | PMID 41672928 Get It

ABSTRACT Background Patients with gastric dysmotility exhibit abnormal transit and reduced contractility, for which quantification is limited with current methodologies. The Atmo Capsule is a wireless motility capsule that measures regional gastrointestinal transit. We tested its technical capabilities to evaluate gastric contractility by detecting changes in capsule acceleration during transit. Methods Data from 91 healthy controls and 182 patients with suspected dysmotility who ingested the Atmo Capsule following a standardized protocol were included. Gastric emptying times (GET) ≥ 5 h were considered delayed. Contraction frequencies (cycles per minute [cpm]) and amplitudes (as arbitrary units [au]) were identified following Fast Fourier Transformation of accelerometer data using 5‐min windows and were assessed in 30‐min windows post‐ingestion (early gastric phase) and before gastric emptying (late gastric phase). Data were compared via ANOVA, using Bonferroni corrections, between healthy controls, patients with normal gastric emptying, and patients with delayed gastric emptying. Key Results Gastric emptying was delayed in 53/182 (29%) patients. Three cpm contraction frequencies were identified across both gastric phases in controls and patients. Contraction amplitudes did not differ between groups in the early gastric phase. In the late phase, mean amplitudes were lower in patients with delayed gastric emptying (6.4 au) compared with subjects with normal gastric emptying (controls, 9.7 au, p < 0.0001; patients, 8.6 au, p < 0.0001). Conclusions & Inference The Atmo Capsule enables precise quantification of gastric contraction profiles, permitting differentiation of normal from pathological motor patterns. Findings of this technical assessment support its potential for evaluating gastric physiology and detecting pathophysiological patterns of gastric dysmotility.
Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology
Kumar, Shaji K., Adekola, Kehinde , Anderson, Larry , Costello, C. L., D’Angelo, Christopher R. , Elsedawy, Noura, Godara, Amandeep , Godby, Kelly, Hillengass, J, Holmberg, Leona, Htut, Myo , Huff, Carol Ann , Hultcrantz, Malin , Kang, Yubin , Larson, Sarah, Lee, Hans Chulhee, Liedtke, Michaela , Martin, Thomas, Omel, James, Robinson, Timothy J., Rosenberg, Aaron, Sherbenou, Daniel, Suvannasankha, Attaya, Valent, Jason , Varshavsky‐Yanovsky, Asya, Ye, J Christine, Kovach, Emily, Kumar, Rashmi , Kumar, Shaji , Callander, Natalie S. , Baljević, Muhamed , Baz, Rachid , Campagnaro, Erica , Costello, Caitlin , Derman, Benjamin A. , Devarakonda, Srinivas , Hillengass, Jens, Holmberg, Leona , Kang, Yubin , Larson, Sarah, Lee, Hans C. , Rosenberg, Aaron , Sarosiek, Shayna , Schroeder, Mark A. , Sherbenou, Daniel W , Suvannasankha, Attaya , Valent, Jason Neil , Vogl, Dan T. , Kovách, E

Mayo Clinic

Journal of the National Comprehensive Cancer Network | January 8, 2026 | Volume: 24 | Issue: 1 | Pages: No page available

10.6004/jnccn.2026.0001 | PMID 41671464 Get It

The treatment landscape for multiple myeloma (MM) is evolving rapidly and includes several new options. The management must be tailored to the individual. The NCCN Guidelines for MM provide a framework to base decisions regarding diagnosis, workup, treatment, and follow-up of both newly diagnosed and previously treated relapsed/refractory MM. This manuscript outlines the recommendations from NCCN Guidelines for MM specific to newly diagnosed MM (NDMM).
POD24 is a novel determinant of prognosis in patients with Waldenström macroglobulinemia
Zanwar, Saurabh , Abeykoon, Jithma P. , D'Sa, Shirley , Larson, Dirk R. , Colby, Colin , Durot, Eric, Kastritis, Efstathios, Uppal, Encarl , Tomkins, Oliver , Morel, Pierre , Montes, Lydia , Paludo, Jonas, Ogunbiyi, Olabisi, Cornillet‐Lefèbvre, Pascale , Rajkumar, S Vincent, Quinquenel, Anne, Gertz, Morie A, Kumar, Shaji , Dimopoulos, M, Ansell, Stephen M., Kapoor, Prashant , D’Sa, Shirley , Abeykoon, Jithma P , Roos-Weil, Damien , Larson, Dirk , Colby, Colin L , Durot, Eric , Kastritis, Efstathios , Uppal, Encarl , Tomkins, Oliver , Morel, Pierre , Mondello, Patrizia , Montes, Lydia , Paludo, Jonas , Ogunbiyi, Olabisi , Cornillet-Lefebvre, Pascale , Quinquenel, Anne , Dispenzieri, Angela , Fonseca, Rafael , Gertz, Morie A , Kumar, Shaji K , Dimopoulos, Meletios A , Treon, Steven , Castillo, Jorge J , Kapoor, Prashant , Durot, Éric , Kastritis, Efstathios , Mondello, Patrizia , Paludo, Jonas , Ailawadhi, Sikander , Sarosiek, Shayna , Rajkumar, S. Vincent , Quinquenel, Anne , Dispenzieri, Angela , Fonseca, Rafaël , Gertz, Morie A. , Dimopoulos, Meletios Α. , Ansell, Stephen M. , Treon, Steven P. , Castillo, Jorge J.

Mayo Clinic

Blood Advances | January 7, 2026 | Volume: 10 | Issue: 7 | Pages: 2322-2327

10.1182/bloodadvances.2025017751 | PMID 41499755 Get It

Abstract Waldenström macroglobulinemia (WM) is characterized by recurrent MYD88 and CXCR4 mutations, whose prognostic value in patients treated with chemoimmunotherapy remains unclear. Moreover, the typically prolonged progression-free survival (PFS) correlates inconsistently with overall survival (OS), underscoring the importance of examining other surrogates. Progression of disease within 24 months (POD24), an established early end point, delineates functionally high-risk patients in other indolent lymphomas. This international study evaluated 253 patients receiving frontline fixed-duration bendamustine-rituximab (BR), a common chemoimmunotherapy for WM. At a median follow-up of 5.9 years, 5-year PFS and OS were 65% and 87%, respectively; 5-year PFS was similar between MYD88L265P (90%) and MYD88wild-type (WT) subcohorts (64% each; P = .4). Among 89 patients with known CXCR4 status, the subcohort with CXCR4mutation (28%) had shorter PFS (median 3.3 vs 8.8 years; hazard ratio [HR], 2.8; P = .0036) and OS (HR, 2.6; P = .036) compared with CXCR4WT. POD24 occurred in 11.5% of patients who demonstrated inferior subsequent OS (5-year OS, 71% vs 86%; HR, 3.1; P = .005) and higher mortality (standardized mortality ratio [SMR], 3.7), unlike the non-POD24 group, whose mortality was comparable to the matched general population (SMR, 1.1). In conclusion, BR is effective irrespective of the MYD88 status, but CXCR4 mutations and POD24 portend worse outcomes. Patients without POD24 represent a cohort with distinctly favorable outcome.
Ibrutinib oral suspension bioavailability and compatibility for optimal enteral administration route
Paludo, Jonas, Nodzon, Lisa , Trixhe, Xavier Woot de , Pacia, Michelle, Mavani, Heena, Atluri, Harisha, Huemann, Thomas J., Shelly, Jessica, Liu, Yemin , Paludo, Jonas , Sarosiek, Shayna

Mayo Clinic

Therapeutic Advances in Hematology | December 24, 2025 | Volume: 16 | Issue: No issue available | Pages: No page available

10.1177/20406207251399466 | PMID 41467123 Get It

Background: Ibrutinib is the only Bruton tyrosine kinase inhibitor (BTKi) with once-daily oral capsule, tablet, and oral suspension formulations approved in the United States across indications of chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström macroglobulinemia, and previously treated chronic graft-versus-host disease, and for mantle cell lymphoma in Europe. Patients with difficulty swallowing capsules or tablets may require alternative formulations or administration options to optimize treatment. Objectives: To evaluate the relative bioavailability of ibrutinib oral suspension relative to capsule or tablet formulations and to examine compatibility for optimal administration methods. Methods: Relative bioavailability of ibrutinib oral suspension was evaluated in healthy volunteers or patients in comparison to capsule or tablet formulations. Dose recovery and delivery, presence of impurities, particle size, and hold time were evaluated after in vitro mock oral suspension administration via syringe and nasogastric and percutaneous endoscopic gastrostomy (PEG) tubes. Results: Clinical bioavailability was comparable for ibrutinib oral suspension and capsules (420 mg/day) under the fasted state in healthy volunteers. Dose-normalized pharmacokinetic values were similar across ibrutinib formulations in patient studies. All evaluated enteral tubes achieved 90%–110% ibrutinib dose recovery regardless of tube type or syringe after 2 × 3 mL water rinses. Oral suspension preservative may be adsorbed into enteral tubes after a 60-minute hold time. Conclusion: Ibrutinib oral suspension bioavailability was comparable with ibrutinib tablet and capsule formulations. When dosed via standard enteral tube administration methods, ibrutinib oral suspension is stable and compatible with polyurethane, silicone, or polyvinyl nasogastric or PEG tubes. To ensure full dose recovery and prevent drug preservative adsorption into tubes, ibrutinib oral suspension should be administered immediately and followed by two rinses of 3 mL of water each. Ibrutinib oral suspension is a viable BTKi treatment option for patients requiring or preferring alternatives to oral capsules and tablets.
Deep responses following treatment with loncastuximab tesirine (WM-NET1 trial) in patients with Relapsed/Refractory including those withhigh-risk, TP53-altered Waldenström macroglobulinemia.
Kwok, Mary , Kapoor, Prashant , Chory, Hannah, Budano, Nina, Nguyen, Julia , Eurell, Alexandra, Meid, Kirsten, Güijosa, Alberto , Tsakmaklis, Nickolas, Treon, Steven, Sarosiek, Shayna , Hunter, Zachary R. , Branagan, Andrew Robert , Treon, Steven P. , Castillo, Jorge J.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 581-581

10.1182/blood-2025-581 Get It

Abstract Introduction: Waldenström macroglobulinemia (WM) is characterized by the presence of a MYD88 mutation in &gt;90% and a CXCR4 mutation in 30-40% of cases. The impact of these mutations on treatment responses and disease outcomes is well known. TP53 alterations (TP53ALT) have more recently been described in WM and are reported to occur in up to 25% of patients, with a higher frequency in patients with previously treated WM, especially those with prior alkylator or nucleoside analogue exposure (Tam et al Blood Adv 2024; Poulain et al CCR 2017; Tsakmaklis et al, ASH 2025). TP53 ALT WM is associated with a shorter time to disease progression, as well as worse overall survival (Poulain et al CCR 2017; Gustine et al, BJH 2019). Depth of response to BTK inhibitors is affected by TP53 status, with recent data reporting a very good partial response (VGPR) rate of 34% v. 25% and major response rates of 84% v. 73% in patients without or with a TP53 ALT (Tam et al Blood Adv 2024). No complete responses were reported and median PFS was shorter in those with a TP53ALT compared with wild-type (TP53WT). Loncastuximab tesirine is a humanized IgG1 anti-CD19 antibody that is conjugated to a pyrrolobenzodiazepine (PBD) dimer. Following internalization, the PBD dimer is released via proteolytic cleavage and binds to the DNA minor groove forming highly cytotoxic DNA inter-strand crosslinks. Cells deficient in DNA repair including TP53 alterations are vulnerable to the cytotoxic effects of loncastuximab tesirine (Tarantelli et al, Haematologica 2024). Methods: In an ongoing investigator-initiated, prospective phase II study in symptomatic patients with relapsed or refractory WM (NCT05190705), patients are receiving single agent loncastuximab tesirine. Loncastuximab tesirine is administered at 150 ug/kg in cycles 1 and 2 and 75 ug/kg in cycles 3 to 6. Each cycle is 28 days. The primary outcome measure of this study is attainment of VGPR or complete (VGPR/CR) response. The accrual goal of this trial is 20 patients, based on an alternative VGPR/CR rate ≥40% versus a null of ≤10%, with a double-sided alpha of 0.037 and a power of 87%. The study would meet its endpoint if ≥6 patients attained a VGPR/CR. Results: Of the 14 patients who have completed therapy on this trial to date, the median age is 71 years (range 53-81), 9 (64%) are male, and the median prior number of therapies is 4 (range 2-10). Median baseline hemoglobin is 9.5 g/dL (range 8.2-12.6), serum IgM is 2146 mg/dL (range 723-5955), and bone marrow involvement is 53% (range &lt;5-90). Four patients had extramedullary disease. Twelve patients (86%) are MYD88 mutated; 8 patients (57%) are CXCR4 mutated, and 8 (57%) are TP53 altered. Nine patients completed all 6 cycles of therapy. Of the 5 other patients, treatment was stopped early due to GGT elevation (n=2), disease progression (n=1), patient decision (n=1), and skin toxicity (n=1). No IgM flare and no infusion reactions have occurred. For all patients, the median time to minor response, major response, and deepest response was 28, 55, and 172 days, respectively. The response rates include 1 (7%) CR; 9 (64%) VGPRs; 2 (14%) partial responses (PR); 1 (7%) minor response; and 1 (7%) progressive disease, for an overall response rate of 93% and a VGPR/CR rate of 71%. For the 8 patients with TP53ALT, the baseline characteristics were as follows: 50% male; median age of 70 years (range 53-77), median prior therapies is 4 (range 2-10); median IgM is 1877 mg/dL (range 723-5639); and median hemoglobin is 9.2 g/dL (range 8.2-11.6). All TP53ALT patients had an MYD88 mutation, and 6 (75%) carried a CXCR4 mutation. For those with TP53 ALT, the median time to minor response, major response, and deepest response was 28, 49, and 235 days, respectively. All TP53ALT patients attained a major response; 1 patient (13%) with a CR, 6 (75%) with a VGPR, and 1 (13%) with a PR, for an overall response rate of 100% and a VGPR/CR rate of 89%. One patient had splenomegaly and one had adenopathy, both of which resolved after treatment. Conclusion: Our findings from this ongoing, prospective trial demonstrate a high VGPR/CR rate of 71% in heavily pre-treated WM. Notable, is the VGPR/CR rate of 89% in high-risk patients with TP53ALT WM. No unexpected toxicities have been seen in this trial. Our findings identify a potentially novel time-limited therapy in relapsed or refractory WM, including patients with high-risk TP53ALT WM.
Deciphering C/EBPα'S Role in Fate Plasticity in Murine and Patient Tissue Derived AT2 Cells
Cai, Jiyang , Sawhney, Amitoj Singh , Deskin, B. , Gibbard, D., Ali, Gibran , Lemire, E., Haber, Adam L. , Wei, Zihao , Bungum, Aaron O., Schrandt, Amy, Cai, Jiyang , Olson, A., Warren, R., Langhe, Stijn De , Inde, Zintis , Sarosiek, Kristopher A. , Brownfield, Douglas

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7930-A7930

10.1164/ajrccm.2025.211.abstracts.a7930 Get It

Abstract RATIONALE: Alveolar Type 2 (AT2) cells play a critical role in maintaining alveolar function and facilitating repair processes in the lung. Despite recent advancement on transcriptomic mapping of cell identities and AT fate selection, the mechanisms governing AT2 fate plasticity remain elusive. Notably, in AT2-derived pulmonary diseases such as COPD and IPF, disruptions in AT2 differentiation are observed, suggesting alterations may exist in the regulation of fate plasticity. Therefore, a refined model describing the regulation of AT2 fate plasticity is needed, along with an assessment of the model's conservation across murine and human AT2s. METHODS: We performed scRNA-sequencing, ATAC-seq, and bioinformatic analysis on samples across murine lung development and validating findings by immunostaining of embryonic lungs. We conducted organotypic cultures as well as genetically engineered mouse model experiments to assess changes in AT2 fate plasticity in. Further, we established a Mayo Clinic patient lung cell biorepository from patient tissue derived AT2s. In parallel, we performed long read scRNA-sequencing for isoform discovery, organotypic culture and immunostaining in human AT2 organoids, to characterize the presence of similar regulatory mechanisms. RESULTS: Throughout the late embryonic and early perinatal period, we found a window of fate plasticity exists in AT2s whereby they retain the capacity to give rise to AT1s, and that its being closed over time by the bZIP transcription factor C/EBPα, as its genetic deletion in AT2s results in regaining fate plasticity. By ATAC-seq and ChIP-seq, we found C/EBPα binds closely to the Dlk1 locus, a Notch signaling regulator implicated in AT2-to-AT1 conversion that is upregulated following Cebpa deletion. Following adult lung injury, we found C/EBPα downregulation is required for re-accessing AT2 fate plasticity and is likely mediated by the dominant negative C/EBP family member CHOP. Finally, we observe Cebpa loss also activates a “defender” AT2 state enriched in interferon stimulated antipathogenic gene expression that is distinct from its reparative state and propose AT2s can toggle between these states following infection to robustly protect and repair alveoli.Further, we validated the presence of C/EBPα and absence of Dlk1 in human AT2s isolated from healthy adult patients, which persists following in vitro expansion. We conclude that AT2 cells window of fate plasticity is dictated by a molecular circuit involving C/EBPα suppressing and Dlk1. Future works aim to remove C/EBPα in human AT2s to reopen their fate plasticity for cell therapy.
Depth of Response From Fixed‐Duration Treatment Is Associated With Superior Survival in Waldenstrom Macroglobulinemia
Abeykoon, Jithma P. , Perera, Nirosha D. , Gustine, Joshua , Ramirez‐Gamero, Andres , Varettoni, Marzia , Tedeschi, Alessandra , Cavalloni, Chiara, Frustaci, Anna Maria , Pederson, Levi , Zanwar, Saurabh , Kapoor, Prashant , Kyle, Robert A. , Geyer, Susan M. , Ansell, Stephen M. , Paludo, Jonas , Sarosiek, Shayna , Varettoni, Marzia , Frustaci, Anna Maria , Pederson, Levi D , Zanwar, Saurabh S , Habermann, Thomas , Witzig, T.E. , Gertz, Morie A , Treon, Steven , Castillo, Jorge J , Ansell, Stephen M , Paludo, Jonas , Habermann, Thomas M. , Witzig, Thomas E. , Gertz, Morie A. , Treon, Steven P. , Castillo, Jorge J.

Mayo Clinic

American Journal of Hematology | March 11, 2025 | Volume: 100 | Issue: 6 | Pages: 980-986

10.1002/ajh.27663 | PMID 40062689 Get It

ABSTRACT As the treatment paradigm for Waldenström macroglobulinemia (WM) continues to evolve, the debate surrounding the prioritization of depth of response versus disease control as therapeutic goals gains significant relevance. However, the impact of depth of response from fixed‐duration therapy on overall survival (OS) was unclear. This multicenter study evaluated the prognostic impact of depth of response using a landmark survival analysis. A total of 440 patients with WM treated with frontline fixed‐duration regimens were included. Attaining a major response (MaR) was associated with superior outcomes, including significantly longer OS. The estimated 5‐year PFS rates for patients with MaR at 6 months versus not were 50% versus 32%, respectively, p < 0.001, and the estimated 5‐year OS rates for patients with MaR at 6 months versus not were 89% versus 70%, respectively, p < 0.001. In a multivariable analysis, MaR at 6 months was independently associated with superior PFS (HR 0.66, p = 0.007) and OS (HR 0.28, p < 0.001). Similar results were seen when considering deeper responses (CR + VGPR vs. PR). Depth of response at 6 months is an important prognostic marker in WM and an independent predictor of PFS and OS. These results support its utilization as a suitable endpoint in clinical studies in WM.
Impact of Constipation Therapies on Severity of Gastroparesis and Constipation Symptoms in Relation to Gastric and Colonic Transit
Surjanhata, Brian , Moshiree, Baharak , Lee, Allen , McCallum, Richard W. , Sarosiek, Irene , Nguyen, Linda Anh B. , Schulman, Michael I., Wo, John M. , Parkman, Henry P. , Surjanhata, Brian C , Nguyen, Linda A , Hasler, William L. , Rao, Satish , Parkman, H P , Lee, Allen A , Kuo, Braden , Rao, Satish S.C.

Mayo Clinic

Neurogastroenterology & Motility | March 11, 2025 | Volume: 37 | Issue: 6 | Pages: No page available

10.1111/nmo.70013 | PMID 40033166 Get It

ABSTRACTIntroductionStudies demonstrate an overlap of constipation with gastroparesis and functional dyspepsia, but the impact of treatments that target constipation on improving upper gastrointestinal (UGI) symptoms is unexplored. We quantified the effects of constipation medication therapies on UGI and constipation symptom severity in subjects presenting with symptoms of gastroparesis.MethodsFifty‐six subjects with symptoms of gastroparesis underwent concurrent wireless motility capsule and gastric emptying scintigraphy and were recommended to receive either a new medication therapy for constipation or a change in constipation therapy based on investigator interpretation of test results. Gastroparesis Cardinal Symptom Index (GCSI), upper abdominal pain, and constipation scores were compared between baseline and 6 months. Data were compared between delayed or non‐delayed gastric emptying and the presence or absence of slow colonic transit.Key ResultsSubjects with slow colonic transit had improvements in GCSI (p = 0.007) and constipation scores (p = 0.004) after treatment with a new or changed constipation medication, with the delayed emptying subgroup driving GCSI improvements (p = 0.004). Reductions in nausea/vomiting (p = 0.02) and early satiety/fullness subscores (p = 0.002) with trends to improved bloating/distention subscores (p = 0.06) were observed in this subgroup, but upper abdominal pain was unchanged. Subjects with normal colonic transit showed no improvement in GCSI scores regardless of gastric emptying status (p > 0.05).Conclusions and InferencesIdentifying and treating delayed colonic transit in gastroparetic (delayed gastric emptying) subjects improves global UGI symptoms as well as selected individual symptoms. Evaluation of whole gut motility as well as recognizing and managing extragastric delay may promote improved outcomes in these patients.Trial RegistrationClinicalTrials.gov: NCT02022826
Duration of Therapy in Patients with Waldenström Macroglobulinemia Undergoing Dose Reductions of First-Line Ibrutinib: A Real-World Analysis
Salkar, Monika, Agatep, Barnabie, Jones, Barton, Pacia, Michelle, Saifan, Chadi , Bacchus, Shaffee, Karve, Sudeep, Sarosiek, Shayna , Paludo, Jonas

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 3728-3728

10.1182/blood-2024-194639 Get It

Background: Continuous single-agent ibrutinib (Ibr) treatment has been associated with extended progression-free survival in patients with Waldenström macroglobulinemia (WM). Previous clinical studies have shown that Ibr dose reductions (DRs) improved or resolved adverse events (AEs) in most patients, while hematologic responses were sustained. However, real-world data on long-term outcomes for patients with WM undergoing Ibr DR in first-line (1L) settings remain limited. Methods: Medicare Fee-for-Service (FFS) medical and pharmacy records were used to identify patients diagnosed with WM who initiated 1L single-agent Ibr (420 mg/day) or 1L Ibr + rituximab from January 1, 2015, to September 30, 2022. Observed patients were enrolled in Medicare FFS ≥12 months before and after 1L treatment initiation and had ≥1 qualifying post-treatment initiation AE of special interest (AESI; both prevalent and incident AEs), as identified via ICD-9-CM or ICD-10-CM diagnosis codes. Ibr DR was defined as a reduction of the starting dose (420 mg/day) following the first AESI during 1L treatment. Patients without an Ibr DR were defined as those who had received Ibr at 420 mg/day during 1L treatment. Patients without an AESI post-Ibr initiation and prior to DR were excluded from the analysis. Demographics, clinical characteristics, time to AESI, duration of therapy (DOT), and time to treatment discontinuation (TTD) were assessed in cohorts with and without DRs. DOT was measured at the date of Ibr treatment initiation through treatment discontinuation (end of 1L treatment). Patients were considered to have discontinued treatment if they received a subsequent systemic therapy after the 1L regimen, had a gap of ≥120 days with no systemic therapy following the last administration, or died while on the 1L regimen. Patients without a discontinuation were censored at the earliest date of end of follow-up or disenrollment. TTD was analyzed using the Kaplan-Meier method. A Cox proportional hazards model adjusted for patient demographics and clinical characteristics was used to identify factors associated with treatment discontinuation. Results: A total of 407 patients with WM were included in the analysis (DR, n=55 [14%]; no DR, n=352 [86%]). Patients in the DR and no DR cohorts, respectively, had similar a median age (78 years vs 77 years), Charlson Comorbidity Index score (3 vs 4), and prevalence of the most common baseline comorbidities: hypertension (67% vs 68%) and cardiovascular conditions (31% vs 28%). The median time between treatment initiation and the occurrence of the first AESI was 89 days versus 76 days, and total Ibr DOT mean ± SD [median] was 786.1 ± 692.6 [661] days versus 454.8 ± 510.4 [279] days (P=0.001) for DR cohort versus no DR cohort. Following DR, patients remained on Ibr for mean ± SD [median] 336.0 ± 422.8 [179] days until the end of 1L therapy. After adjusting for variations in baseline characteristics, patients with a DR had significantly longer TTD post-treatment initiation than those without a DR (median TTD, DR vs no DR: 22.5 months vs 9.3 months; adjusted HR [95% CI], 0.52 [0.37-0.72]). Conclusion: This real-world evidence study suggests that implementing DRs to manage AEs can be a valuable strategy in supporting patients with WM to remain on 1L Ibr longer, thus maintaining beneficial clinical outcomes. These findings are consistent with previous studies, demonstrating that Ibr DRs help to improve tolerability while maintaining treatment efficacy.